Male Infertility Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Male infertility is defined as the inability to achieve pregnancy after 12 months of regular unprotected intercourse in the presence of a female partner with normal fertility. Male factor contributes to approximately 40–50% of all infertility cases, either as the sole cause (20–30%) or as a contributing factor alongside female factors. Despite this, male infertility has historically been underdiagnosed and undertreated — evaluation of both partners simultaneously at the outset of infertility investigation is now standard of care. Spermatogenesis — the production of mature spermatozoa — occurs in the Sertoli cell-lined seminiferous tubules of the testes under hormonal control by follicle-stimulating hormone (FSH) and testosterone. The process takes 74 days, followed by 12–21 days of sperm maturation in the epididymis. This biological timeline means that environmental or toxic insults affect semen quality with a 3-month lag, and interventions require 3 months before improvement is detectable in semen analysis. WHO 2021 reference values (fifth percentile of fertile men fathering a child within 12 months): semen volume 1.4 mL, sperm concentration 16 million/mL, total motility 42%, progressive motility 30%, normal morphology 4% (Kruger strict criteria). Azoospermia — absence of sperm in the ejaculate — is found in 1% of all men and 10–15% of infertile men, and is classified as obstructive (OA — blocked ductal system, normal spermatogenesis) or non-obstructive (NOA — impaired spermatogenesis). Understanding the distinction between OA and NOA is critical as it determines management: OA is amenable to surgical reconstruction or sperm retrieval, while NOA requires surgical sperm retrieval combined with ICSI, or in severe cases, donor sperm.

Male infertility treatment addresses a spectrum of aetiologies. Varicocele — dilation of the pampiniform venous plexus — is the most surgically correctable cause, present in 35–40% of infertile men. Varicoceles raise intratesticular temperature and create reactive oxygen species that damage sperm DNA, reducing motility, morphology, and count. Surgical or interventional treatment improves semen parameters in 60–70% of men and achieves spontaneous pregnancy in 30–40% within 24 months. Obstructive azoospermia results from ductal obstruction at the epididymis, vas deferens, or ejaculatory duct: congenital bilateral absence of the vas deferens (CBAVD — associated with CFTR mutations), post-vasectomy obstruction, post-infective epididymal obstruction, and ejaculatory duct obstruction. Surgical reconstruction (vasovasostomy, vasoepididymostomy) or sperm retrieval for ART are treatment options. Non-obstructive azoospermia reflects impaired spermatogenesis: Klinefelter syndrome (47,XXY — the most common genetic cause, affecting 1 in 650 men), Y chromosome microdeletions (AZFa, AZFb, AZFc regions), cryptorchidism, post-chemotherapy or radiation gonadotoxicity, hypogonadism, and idiopathic causes. Hormonal deficiencies: hypogonadotropic hypogonadism (congenital — Kallmann syndrome; or acquired — pituitary adenoma, haemochromatosis) is a treatable cause of azoospermia, responding to gonadotropin therapy (FSH + hCG) with restoration of spermatogenesis. Lifestyle factors — tobacco smoking (reduces sperm count 15–17%), excessive alcohol, anabolic steroid use (causes testicular atrophy and suppressed gonadotropins), obesity, heat exposure, and occupational toxic exposures — are modifiable causes of impaired semen quality.

Male infertility evaluation begins with a detailed reproductive and medical history: infertility duration, prior pregnancies, sexual function, scrotal or groin surgery, urogenital infections, systemic illness, medications (including anabolic steroids, testosterone — which suppresses spermatogenesis), and chemotherapy or radiation exposure. Physical examination: testicular volume (normal 15–25 mL per orchidometer), testicular consistency, epididymal fullness, presence of vas deferens bilaterally (absent in CBAVD), and varicocele assessment (clinical grade I–III). Two semen analyses, 4–6 weeks apart (after 2–5 days of sexual abstinence), form the diagnostic foundation. If both analyses are normal, male factor is excluded and evaluation is directed to female factors. Abnormal semen analysis triggers further evaluation: serum FSH, LH, total testosterone, and prolactin; genetic testing (karyotype for Klinefelter syndrome; Y chromosome microdeletion for NOA with concentration below 5 million/mL); and CFTR mutation analysis for CBAVD. Antisperm antibody testing is indicated when sperm agglutination or markedly reduced forward progression is observed. Testicular ultrasound identifies varicocele, testicular microlithiasis, and testicular masses. Testicular biopsy (or microsurgical testicular sperm extraction — microTESE) for NOA serves both diagnostic (maturation arrest, hypospermatogenesis, Sertoli cell-only) and therapeutic (sperm retrieval for ICSI) purposes.

Treatment is matched to the underlying cause and severity of impairment. Lifestyle modification is foundational for all men: cessation of anabolic steroids and exogenous testosterone (requires 3–12 months to restore spermatogenesis), smoking cessation, BMI reduction to below 25, alcohol limitation, scrotal cooling, and avoidance of testicular heat (hot tubs, saunas, tight underwear). Antioxidant supplementation (vitamin C, vitamin E, coenzyme Q10, zinc, selenium, folic acid, lycopene) reduces oxidative sperm DNA damage with modest improvement in semen parameters and live birth rates in placebo-controlled trials. Hormonal therapy for hypogonadotropic hypogonadism: hCG (1,500–3,000 IU three times weekly) with or without FSH (75–150 IU three times weekly) restores intratesticular testosterone and stimulates spermatogenesis. Clomiphene citrate and letrozole (oral anti-oestrogens) increase endogenous FSH and testosterone in idiopathic oligospermia. Varicocele treatment: microsurgical subinguinal varicocelectomy (the preferred approach — lowest recurrence rate 0.5–1%, lowest hydrocele rate less than 1%, preserving testicular arterial and lymphatic supply) or percutaneous retrograde embolisation (IR procedure — equivalent outcomes to open surgery). Surgical sperm retrieval: percutaneous epididymal sperm aspiration (PESA), testicular sperm aspiration (TESA), testicular sperm extraction (TESE), and microsurgical TESE (microTESE — the gold standard for NOA, identifying focal areas of spermatogenesis under optical magnification, achieving sperm retrieval in 40–60% of NOA). Vasovasostomy (vasectomy reversal) and vasoepididymostomy reconstruct ductal obstruction for OA. Intrauterine insemination (IUI): processed sperm inserted directly into the uterine cavity at ovulation — effective for mild oligospermia, unexplained infertility, or hostile cervical mucus. IVF with intracytoplasmic sperm injection (ICSI): a single viable sperm microinjected directly into a mature oocyte — the definitive ART for severe oligospermia, poor morphology, or surgically retrieved sperm.

Lifestyle modification and cessation of gonadotoxins can restore semen parameters to normal in men with reversible causes — anabolic steroid cessation restores spermatogenesis in 80–90% of men within 12 months. Antioxidant therapy improves sperm concentration, motility, and morphology by 10–20% in oxidative stress-related oligospermia, with a meta-analysis suggesting 4-fold improvement in live birth rates. Microsurgical varicocelectomy improves semen parameters in 60–70% of men — concentrations increase on average from 15 to 30 million/mL, motility from 30% to 50% — and achieves spontaneous pregnancy in 30–40% within 24 months at a fraction of IVF cost. Gonadotropin therapy for hypogonadotropic hypogonadism restores spermatogenesis in 75–90% of men, with pregnancy rates comparable to those in the general fertile population. Vasovasostomy achieves patency rates of 70–90% (sperm present in ejaculate) and pregnancy rates of 30–75% depending on obstructive interval — best results with less than 3 years since vasectomy (patency 97%, pregnancy 76%). MicroTESE for NOA retrieves sperm in 40–60% of men with Sertoli cell-only histology and up to 50–60% with maturation arrest, enabling ICSI that would otherwise require donor sperm. IVF/ICSI live birth rates: 40–45% per cycle under age 35, declining to 25–30% at 35–40 years and below 15% after 40 for female partner age.

Hormonal therapies: clomiphene and gonadotropins are generally well-tolerated but can cause mood changes and gynaecomastia. Gonadotropin therapy requires injections 3 times weekly and careful monitoring. Exogenous testosterone administration causes azoospermia in 90% of men within 3 months and is contraindicated for men pursuing fertility. Varicocelectomy risks: hydrocele formation (1–5% with open techniques; less than 1% with microsurgical approach), testicular artery injury (rare with microsurgery, less than 0.5%), and varicocele recurrence (1–2% microsurgical vs 5–15% laparoscopic). PESA and TESA: bruising and haematoma at puncture site (5–10%), temporary discomfort, and a theoretical risk of epididymal fibrosis with repeated aspirations, which may compromise future epididymal reconstructive surgery. MicroTESE: surgical risks of scrotal wound complication (less than 2%), postoperative haematoma (1–3%), and potential permanent reduction in testicular testosterone production from biopsy of glandular tissue. Vasovasostomy and vasoepididymostomy are technically demanding microsurgical procedures requiring a highly skilled microsurgeon; anastomotic failure rates are 10–30% depending on the level of reconstruction. IVF/ICSI: multiple gestation risk if multiple embryos transferred; ovarian hyperstimulation syndrome (OHSS) in the female partner; and the emotional burden of repeated failed cycles. The genetic transmission of Y chromosome microdeletions (AZFc region specifically) to male offspring via ICSI is a concern requiring genetic counselling.

Semen analysis is repeated 3 months after any intervention — the duration of a full spermatogenic cycle — to assess treatment response. After varicocelectomy, semen analysis at 3, 6, and 12 months documents progressive improvement; spontaneous pregnancy attempts are appropriate from 3 months post-procedure. If pregnancy has not occurred by 12–18 months after varicocelectomy with good semen improvement, IUI or IVF/ICSI is considered. After gonadotropin therapy for hypogonadotropic hypogonadism, semen analysis monthly monitors spermatogenic response; FSH, LH, and testosterone levels guide dose adjustments. After vasovasostomy or vasoepididymostomy, semen analysis at 1 month, 3 months, and 6 months assesses anastomotic patency and progressive improvement. If patency is confirmed but pregnancy has not occurred by 12 months, IUI or ICSI with ejaculated sperm is pursued. Cryopreservation of sperm at any successful retrieval point — after varicocelectomy improvement, at microTESE, or at vasectomy reversal — is recommended as insurance for future ART cycles without repeat surgery. Annual review of the couple's fertility status, considering advancing female partner age, guides the pace of further treatment escalation.

Male infertility evaluation (semen analysis, hormones, genetic testing): India USD 100–400; USA USD 500–2,000. Varicocele embolisation: India USD 1,000–2,500; USA USD 5,000–12,000. Microsurgical varicocelectomy: India USD 800–2,000; Thailand USD 2,000–5,000; USA USD 5,000–15,000. Vasovasostomy (vasectomy reversal): India USD 1,500–4,000; USA USD 5,000–15,000; UK GBP 3,000–8,000. MicroTESE: India USD 2,000–5,000; USA USD 8,000–20,000. PESA/TESA: India USD 500–1,500; USA USD 3,000–8,000. IUI cycle (including monitoring and insemination): India USD 300–700; USA USD 1,000–3,000. IVF/ICSI cycle (including egg retrieval, fertilisation, embryo transfer): India USD 2,500–5,000; Thailand USD 4,000–8,000; Czech Republic USD 3,500–6,500; USA USD 12,000–25,000; UK GBP 5,000–10,000. Embryo freezing per year: India USD 300–700; USA USD 500–1,500. Donor sperm (anonymous): India USD 200–500; USA USD 1,000–3,000. Medical tourism to India, Czech Republic, or Thailand for IVF/ICSI saves 60–80% versus US costs, with equivalent success rates at accredited reproductive medicine centres.

Donor sperm insemination (DI) with IUI or IVF is the primary alternative for men with non-obstructive azoospermia in whom microTESE fails to retrieve sperm, or for men with severe genetic conditions (Y chromosome AZFa/AZFb deletions — where sperm retrieval is futile). Anonymous or open-identity sperm donors are available through licensed sperm banks worldwide. Adoption and child-free living are valid alternatives for couples who decline ART or for whom treatment has been unsuccessful. Oral empirical antioxidant therapy (CoQ10 200–400 mg daily, vitamin E 400 IU, vitamin C 1,000 mg, zinc 25 mg, selenium 100 mcg) represents a low-risk, low-cost trial for idiopathic oligospermia where no surgical cause is identified — a 3–6 month trial is reasonable before escalating to IVF. Electroejaculation or vibratory penile stimulation retrieves sperm in men with spinal cord injury or anejaculation from autonomic neuropathy, enabling IUI or IVF/ICSI without invasive surgical retrieval. Retrograde ejaculation (sperm directed into the bladder rather than expelled via the urethra — from diabetes, retroperitoneal surgery, or sympatholytic medications) is managed with alkalinisation of the bladder (oral bicarbonate before ejaculation) and post-void bladder urine centrifugation to retrieve sperm for IUI/ICSI.